Jazz dou­bles down on sleep dis­or­ders, putting down $50M cash to pluck Sum­it­o­mo drug for the pipeline

Mere weeks af­ter di­vest­ing a com­mer­cial treat­ment for ex­ces­sive day­time sleepi­ness, Jazz Phar­ma­ceu­ti­cals has in-li­censed an ear­ly-stage pro­gram to test a new tar­get for a range of sleep dis­or­ders.

For $50 mil­lion up­front, Sum­it­o­mo Phar­ma is hand­ing over rights to de­vel­op an oral orex­in-2 re­cep­tor ag­o­nist that’s been through Phase I. Where­as Jazz will de­vel­op the drug in the US, Eu­rope and oth­er un­spec­i­fied ter­ri­to­ries, the Japan­ese drug­mak­er is re­tain­ing Japan, Chi­na and oth­er Asia-Pa­cif­ic re­gion­al rights.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER